Senate Finance Has No Jurisdiction Over VNS Approval – Cyberonics’ Cummins
This article was originally published in The Gray Sheet
Executive Summary
An ongoing Senate Finance Committee inquiry into Cyberonics' February "approvable" letter will not hinder approval of VNS Therapy for treatment-resistant depression, CEO Skip Cummins asserted in a May 19 conference call